Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy
- 55 Downloads
The aim of the project was to assess the effectiveness and safety of weekly epoetin-beta (EB) in patients with gastrointestinal cancer (GIC) subjected to concomitant chemoradiotherapy (CCTRT).
In this clinical prospective and multicentre cohort study EB was administered at a dose of 30,000 IU/ week, during CCTRT and in the four weeks thereafter, and suspended if haemoglobin (Hb) increased >2 g/dl or Hb >12–13 g/dl. Effectiveness was defined as Hb increase ≥1 g/dl vs. baseline. Time to response, treatment toxicity and transfusion requirements were also assessed.
EB was effective in 75.8% of the evaluable population within a median of four weeks from EB initiation, without blood transfusions. Over 80% of all patients remained below the threshold (Hb ≤13 g/dl) and no study drug-related adverse reactions were recorded.
Weekly EB proved to be effective and well tolerated by patients with GIC subjected to CCTRT.
KeywordsGastrointestinal cancer Epoetin-beta Anaemia
Unable to display preview. Download preview PDF.
- 1.Blohmer JU, Dunst J, Harrison L et al (2005) Cancer-related anaemia: biological findings, clinical implications and impact on quality of life The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Oncology 68[Suppl 1]:12–21PubMedCrossRefGoogle Scholar
- 12.Aapro M, Leonard RC, Barnadas A et al (2008) Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26:592–598PubMedCrossRefGoogle Scholar
- 15.Ray-Coquard I, Tourani J, Facon T et al (2007) Epoetin beta treatment of chemotherapy induced anemia in cancer patients: results of a large prospective cohort study. J Clin Oncol (Meeting Abstracts) 25:19582Google Scholar
- 16.Salgado M, Gómez A, Valladares M et al (2008) Efficacy of epoetin-beta 30,000 iu/week in correcting anemia in patients with gastrointestinal tumors subjected to concomitant chemo-radiotherapy. ASCO. Gastrointestinal Cancers Symposium. Category: Colon and Rectum — Multidisciplinary Treatment, Abstract No. 517Google Scholar
- 18.Heras P, Kritikos K, Hatzopoulos A, Mitsibounas D (2008) Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study. Eur J Cancer Care (Engl) 17:619–623Google Scholar
- 22.Demetri GD (2006) Evidence-based use of hematopoietic growth factors for optimal supportive care of patients with cancer. Oncology 1535–1544Google Scholar
- 24.Dalton J, Bailey N, Barrett-Lee P, O’Brien M (1998) Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Oncol 17:418a (Abstract 1611)Google Scholar
- 29.Moehler MH, Geissler M, Raedle J et al (2007) Erythropoetin (epoetin beta) once weekly in anemic patients with advanced cancer of the stomach or gastroesophageal junction: interim results of a randomized German AIO phase II trail. J Clin Oncol (Meeting Abstracts) 25:15133Google Scholar